MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Sophiris Bio Company Profile (NASDAQ:SPHS)

Consensus Ratings for Sophiris Bio (NASDAQ:SPHS) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.50 (123.88% upside)

Analysts' Ratings History for Sophiris Bio (NASDAQ:SPHS)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Echelon Wealth PartnersReiterated RatingBuy$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/10/2016Maxim GroupReiterated RatingBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2014Stifel NicolausDowngradeBuy -> Hold$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2014Leerink SwannInitiated CoverageOutperform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Sophiris Bio (NASDAQ:SPHS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/5/2016        
5/16/2016Q1($0.19)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q4($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/16/2015Q3($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015($0.30)($0.26)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2015($0.47)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.54)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.50)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Sophiris Bio (NASDAQ:SPHS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Sophiris Bio (NASDAQ:SPHS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Sophiris Bio (NASDAQ:SPHS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/15/2014Boxer Capital, LlcMajor ShareholderSell881,479$0.61$537,702.19View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2014Randall E WoodsInsiderBuy3,000$2.43$7,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Gerald T ProehlDirectorBuy10,000$3.16$31,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2014Randall E WoodsInsiderBuy1,000$2.65$2,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2014Randall E WoodsInsiderBuy1,000$2.66$2,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014James L HeppellDirectorSell19,231$2.59$49,808.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2013Randall E WoodsCEOBuy2,500$4.50$11,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Peter T SloverCFOBuy4,680$4.25$19,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/19/2013Randall E WoodsCEOBuy10,000$4.29$42,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2013Boxer Capital, LlcMajor ShareholderBuy1,600,000$5.00$8,000,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Sophiris Bio (NASDAQ:SPHS)
DateHeadline
06/27/16 06:26 PMWatching Stock Sentiment for:Sophiris Bio, Inc. (NASDAQ:SPHS) - Press Telegraph
06/27/16 06:26 PMSophiris Bio, Inc. (NASDAQ:SPHS) Recent Performance and Company Stock Review - Engelwood Daily
06/27/16 10:32 AMNext Weeks Broker Price Targets For Sophiris Bio, Inc. (SPHS) - Fiscal Standard
06/25/16 05:55 PMSophiris Bio, Inc. (NASDAQ:SPHS): Update on Stock Performance - Press Telegraph
06/25/16 05:55 PMStrong Sell Calls Recommendations For Sophiris Bio, Inc. (NASDAQ:SPHS) At 0 - Investor Newswire
06/24/16 09:05 AMBrokers Issue Average Price Target Of 5.50 On Sophiris Bio, Inc. (SPHS) - Fiscal Standard
06/24/16 09:05 AMImpact Score Outlook on:Sophiris Bio, Inc. (NASDAQ:SPHS) - Press Telegraph
06/23/16 07:13 PMStock Watch for: Sophiris Bio, Inc. (NASDAQ:SPHS) - Press Telegraph
06/23/16 07:13 PMSophiris Bio, Inc. (NASDAQ:SPHS): Share Update and Performance Review - Press Telegraph
06/20/16 08:01 AMStrong Buy Calls Count For Sophiris Bio, Inc. (NASDAQ:SPHS) At 1 - Investor Newswire
06/20/16 08:01 AMThis Weeks Broker Views For Sophiris Bio, Inc. (SPHS) - Fiscal Standard
06/17/16 09:10 AMHave a look at Price Moves: Sophiris Bio, Inc. (NASDAQ:SPHS) , Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) - Street Updates
06/16/16 06:43 PMTwo Stocks within Analysts Review: Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) , Sophiris Bio, Inc. (NASDAQ ... - Street Updates
06/15/16 10:27 AMAgios Pharmaceuticals (NASDAQ:AGIO) Receives 'Buy' Rating From Canaccord Genuity
06/14/16 10:36 AMNotable movements of HC Stocks: Skyline Medical Inc (NASDAQ:SKLN), Sophiris Bio Inc (NASDAQ:SPHS) - share market updates (press release)
06/12/16 06:36 PMEye-Catching Stocks - Apple, (NASDAQ:AAPL), Sophiris Bio, (NASDAQ:SPHS) - Wall Street 24
06/12/16 09:09 AMSophiris Soars on Positive Phase 2 Results
06/12/16 09:09 AMSophiris Bio Inc. (SPHS) Has Jumped To A 4-Month High On Study Results
06/12/16 09:09 AMSophiris Bio shares rocket after Phase 2a success in prostate cancer treatment
06/11/16 09:27 AMHome Breaking News Sophiris Bio | $SPHS Stock | Shares Surge On Positive Phase 2a... - TickerTV News (press release)
06/10/16 06:52 PMEchelon Analyst Comments on Sophiris Bio Inc (SPHS) Following Positive Prostate Cancer Data - Smarter Analyst
06/10/16 02:43 PMMid-Afternoon Market Update: Dow Falls Over 150 Points; Crude Oil Down 2.5% - Toward the end of trading Friday, the Dow traded down 0.92 percent to 17,820.66 while the NASDAQ declined 1.42 percent to 4,888.05. The S&P also fell, dropping 1.13 percent to 2,091.65. Leading and Lagging Sectors On Friday, non-cyclical consumer goods & services shares slipped by just 0.5 percent. In trading on Friday, energy shares tumbled by 2.5 percent. Meanwhile, top losers in the sector included Baytex Energy Corp (USA) (NYSE: BTE), down 10 percent, and Cobalt International Energy, Inc. (NYSE: CIE), down 10 percent. Top Headline Westlake Chemical Corporation announced plans to acquire Axiall Corp for $33.00 per share in all-cash transaction. The transaction is likely to complete by the fourth quarter of 2016. Equities Trading UP Sophiris Bio Inc (NASDAQ: SPHS) shares shot up 89 percent to $2.21 after the company reported successful results ...Full story available on Benzinga.com
06/10/16 12:58 PM8 Biggest Mid-Day Gainers For Friday - Sophiris Bio Inc (NASDAQ: SPHS) shares jumped 89.74 percent to $2.22 after the company reported successful results from Phase 2a trial of topsalvsin in localized prostate cancer. New Concept Energy, Inc. (NYSE: GBR) surged 65.92 percent to $2.97. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) shares gained 38.80 percent to $57.56. Axiall Corp (NYSE: Full story available on Benzinga.com
06/10/16 09:34 AMMaxim Weighs In on Sophiris Bio Inc (SPHS) Following Positive Phase IIa Results In Prostate Cancer - Smarter Analyst
06/10/16 09:34 AMSophiris Bio Inc (SPHS), Global Blood Therapeutics Inc (GBT), GigPeak Inc (GIG), and Jaguar Animal Health Inc (JAGX ... - TCC
06/10/16 09:19 AMFriday’s Most Buzzworthy Stocks: Antero, Valeant, Southwestern Energy, More -
06/10/16 07:13 AMSophiris Bio's stock more than doubles after prostate cancer treatment's successful test results -
06/10/16 06:50 AMSophiris Bio Up 113% After Successful Results From Phase 2a Trial Of Topsalvsin In Localized Prostate Cancer -
06/09/16 07:02 PMSophiris Bio (SPHS) Announces Biopsy Results from 18 Patients Enrolled in Phase 2a Study of Topsalysin - StreetInsider.com
06/09/16 04:29 PMSophiris shares rally on promising cancer treatment study -
06/09/16 03:19 PMSophiris Bio Reports Successful Results from Completed Phase 2a Study of Topsalysin in Localized Prostate Cancer - [at noodls] - SAN DIEGO and VANCOUVER, British Columbia, June 9, 2016 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the 'Company' or 'Sophiris'), a biopharmaceutical company developing PRX302 (topsalysin) for the ...
06/09/16 03:01 PM4:01 pm Sophiris Bio announces biopsy results from 18 patients enrolled in the phase 2a proof of concept study of topsalysin in localized prostate cancer -
06/07/16 09:19 AMTwo Movers inside Traders Radar: Stryker Corporation (NYSE:SYK) , Sophiris Bio, Inc. (NASDAQ:SPHS) - Street Updates
06/06/16 06:39 PMEarnings Trends of the Stocks: Nimble Storage, Inc. (NYSE:NMBL), Sophiris Bio, Inc. (NASDAQ:SPHS) - Beacon Chronicle
06/06/16 06:39 PMSophiris Bio, Inc. (NASDAQ:SPHS) at $1.09: How much higher it can go - iStreetWire
06/06/16 10:32 AMSophiris Bio (NASDAQ:SPHS) at $1.09: How much higher it can go - iStreetWire
06/04/16 06:36 PMSophiris Bio, Inc. (NASDAQ:SPHS): Stock Performance Recap - HNN
06/04/16 06:36 PMTarget Price Review Sophiris Bio, Inc. (NASDAQ:SPHS) - HNN
06/02/16 07:00 PMSophiris Bio, Inc. (NASDAQ:SPHS): Rundown on Share Performance - HNN - Sophiris Bio, Inc. (NASDAQ:SPHS): Rundown on Share PerformanceHNNIn the latest trading period, Sophiris Bio, Inc. (NASDAQ:SPHS) shares have seen a change of -0.0808%. During the period, the stock has moved up to a high of $1.0000 and dipped to a low of $0.9725. Looking at a broader view of stock performance, shares ...and more »
06/02/16 09:42 AMTarget Price Outlook on Sophiris Bio, Inc. (NASDAQ:SPHS) - HNN - Target Price Outlook on Sophiris Bio, Inc. (NASDAQ:SPHS)HNNEquity analysts that track Sophiris Bio, Inc. (NASDAQ:SPHS) shares have provided targets on where they believe the stock will move in the future. The present consensus target price compiled using analysts polled by Zacks Research sits at $4. There are ...and more »
06/02/16 09:42 AMBroker Watchlist: Sophiris Bio, Inc. (SPHS) - Share Trading News - Broker Watchlist: Sophiris Bio, Inc. (SPHS)Share Trading News12/02/2013 – Citigroup began new coverage on Sophiris Bio, Inc. giving the company a “neutral” rating. They now have a USD 4.5 price target on the stock. The share price of Sophiris Bio, Inc. (SPHS) was down -0.02% during the last trading session, with ...Brokerage Views in Focus: Plug Power, Inc. (NASDAQ:PLUG), Palo Alto Networks, Inc. (NYSE:PANW), Sophiris Bio, Inc ...News Tribuneall 4 news articles »
06/01/16 07:09 PMStock Sentiment Update:Sophiris Bio, Inc. (NASDAQ:SPHS) - HNN - Stock Sentiment Update:Sophiris Bio, Inc. (NASDAQ:SPHS)HNNSophiris Bio, Inc. (NASDAQ:SPHS) has a current news sentiment score of -0.217. This data is given by Beta Research. On a scale between 1 and -1, a score of 1 would represent the news sentiment being positive. On the opposite side, a score of -1 would ...and more »
05/31/16 06:54 PMSophiris Bio, Inc. (NASDAQ:SPHS): Review of Stock Performance - HNN - Sophiris Bio, Inc. (NASDAQ:SPHS): Review of Stock PerformanceHNNDuring the most recent trading session, shares of Sophiris Bio, Inc. (NASDAQ:SPHS) have moved -2.0303%. During the period, shares have moved to a high of $1.0199 and fell to a low of $0.9500. Broadening the view, the stock has range traded from ...
05/30/16 04:24 PMPrice Target in View Sophiris Bio, Inc. (NASDAQ:SPHS) - HNN - Price Target in View Sophiris Bio, Inc. (NASDAQ:SPHS)HNNSophiris Bio, Inc. (NASDAQ:SPHS) has been provided a consensus price target of $4 on shares. Out of all the Wall Street analysts polled by Zacks Research that were included for this target, the analyst with the highest price target sees the stock ...
05/30/16 04:24 PMStock Impact Score Review :Sophiris Bio, Inc. (NASDAQ:SPHS) - HNN - Stock Impact Score Review :Sophiris Bio, Inc. (NASDAQ:SPHS)HNNSophiris Bio, Inc. has been provided an impact score of 0 by Beta Research. The impact score represents an average projection of how reported news in the past day may impact the stock price. A high impact score may signal that the stock could see ...and more »
05/30/16 04:24 PMStock Performance Review : Sophiris Bio, Inc. (NASDAQ:SPHS) - HNN - Stock Performance Review : Sophiris Bio, Inc. (NASDAQ:SPHS)HNNShares of Sophiris Bio, Inc.(NASDAQ:SPHS) have been recently seen at -74.29% away from the 52 week high and 47.76% separated from the 52 week low. If we move in a bit closer, the stock has been recently recorded at -46.49% away from the 50 day high ...and more »
05/30/16 04:24 PMSophiris Bio, Inc. (SPHS) Broker Price Targets For The Coming Week - Share Trading News - Sophiris Bio, Inc. (SPHS) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Sophiris Bio, Inc. (SPHS). The latest reports which are currently in issue on Monday 30th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 ...Sophiris Bio Incorporated (NASDAQ:SPHS) Short Interest Increased By 35.84%Franklin Independentall 3 news articles »
05/28/16 04:20 PMView on Earnings Sophiris Bio, Inc. (NASDAQ:SPHS) - HNN - View on Earnings Sophiris Bio, Inc. (NASDAQ:SPHS)HNNSell-side analysts that cover Sophiris Bio, Inc. (NASDAQ:SPHS) are expecting the company to report earnings for the quarter of $N/A. The consensus estimate uses covering analysts polled by Zacks Research. The estimate may vary from what other data ...
05/27/16 09:46 PMSophiris Bio, Inc. (NASDAQ:SPHS) Sell-Side Outlook on the Shares - Stock Tick Tock - Sophiris Bio, Inc. (NASDAQ:SPHS) Sell-Side Outlook on the SharesStock Tick TockThe Wall Street sell-side, who serve as intermediaries between stock issuers and investors, have a consensus target price of $4 on Sophiris Bio, Inc. (NASDAQ:SPHS) shares. The most aggressive analyst target sees the stock reaching $4 within the next ...and more »
05/27/16 07:16 AMInvestors Spotlight: Sophiris Bio, Inc. (NASDAQ:SPHS) , Cempra, Inc. (NASDAQ:CEMP) - Street Updates - Investors Spotlight: Sophiris Bio, Inc. (NASDAQ:SPHS) , Cempra, Inc. (NASDAQ:CEMP)Street UpdatesOn 5/26/2016, shares of Sophiris Bio, Inc. (NASDAQ:SPHS) rose +7.53% in trading session and finally closed at $1.00. The company most recent volume stood at 846.99 thousand shares as compared to its average volume of 313.78 thousand shares.
About Sophiris Bio

Sophiris Bio logoSophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SPHS
  • CUSIP:
Key Metrics:
  • Previous Close: $2.01
  • 50 Day Moving Average: $1.33
  • 200 Day Moving Average: $1.57
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $41.84M
  • Current Quarter EPS Consensus Estimate: $-0.73 EPS
Additional Links:
Sophiris Bio (NASDAQ:SPHS) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha